PDF(Sci-hub)
Abstract：
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. It is highly responsive to chemotherapy, but the median event-free survival is very short and has a high rate of relapse even after performing allogeneic stem cell transplantation; thus, the discovery of novel agents for the treatment of BPDCN is urgent. Chidamide is a new oral isotype-selective histone deacetylase inhibitor (HDACi). It is proved to exert a well-characterized anticancer property in a wide range of hematological malignancies, especially lymphoma. Here, we report a 41-year-old man who used oral chidamide 30 mg twice per week for maintenance therapy after receiving complete remission. For the first time in this field, we had explored the efficiency of chidamide in the treatment of BPDCN and tried to give more choices to the therapy of this disease.
摘要：
母细胞性浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见且侵袭性的造血系统恶性肿瘤，主要影响老年患者。它对化疗反应强烈，但中位无事件生存期非常短，即使在进行异基因干细胞移植后，复发率也很高；因此，迫切需要发现治疗BPDCN的新药物。Chidamide是一种新型的口服同种型选择性组蛋白脱乙酰酶抑制剂（HDACi）。它被证明在广泛的血液恶性肿瘤中具有良好的抗癌特性，尤其是淋巴瘤.这里,我们报道了一名41岁的男性患者,他在获得完全缓解后,每周两次口服西达本胺30mg进行维持治疗.在这个领域第一次，我们探讨了西达本胺治疗BPDCN的疗效,并试图为本病的治疗提供更多选择.
